Systemic sclerosis & Raynaud's
Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?
Study context
- Population
- Patients with SSc-ILD with extent of fibrotic ILD on HRCT of >10%; median time since first non-Raynaud symptom 3.4 years; almost half on stable mycophenolate at baseline
- Participants
- 576 patients
- Comparison
- Nintedanib vs placebo
Primary result
As reported in the abstract
Key findings of the SENSCIS trial
At baseline, patients without cough
20%
At baseline, patients without dyspnoea
30%
Forced vital capacity (FVC) decline in placebo, dcSSc, over 52 weeks
−112.0 mL/year
FVC decline in placebo, lcSSc, over 52 weeks
−74.5 mL/year
Further findings
Skin fibrosis and health-related quality of life
- No significant effect of nintedanib
Original publication
Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial? Clin Exp Rheumatol. Published 3 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →